TABLE 1.

Main disease characteristics of 146 dogs with immune‐mediated hematological disorders. Treatment included membrane‐based therapeutic plasma exchange (mTPE group) or was limited to immunosuppressive treatment (controls)

Variable	Unit	mTPE group (n = 17)	Controls (n = 129)	P
IMHA (n = 70)		n = 7	n = 63
Hematocrit	L/L	0.14 (0.13‐0.15)	0.13 (0.10‐0.18)	.82
Reticulocytes	109/L	107 (49‐185)	137 (59‐238)	.42
Platelets	109/L	267 (234‐334)	208 (148‐284)	.16
Bilirubin	μmol/L	37.8 (4.1‐58.6)	20.8 (9.6‐46.6)	.98
APPLEfast score a		24.0 (20.5‐25.0)	25.5 (21.5‐29.0)	.24
Idiopathic IMHA		5 (71%)	50 (79%)	.64
Secondary IMHA		2 (29%)	13 (21%)
IMT (n = 52)		n = 5	n = 47
Hematocrit	L/L	0.31 (0.26‐0.36)	0.28 (0.20‐0.39)	.84
Reticulocytes	109/L	50 (4‐53)	86 (65‐183)	.04*
Platelets	109/L	4 (2‐4)	6 (5‐18)	.06
APPLEfast score b		24.0 (21.5‐26.5)	26.0 (20.0‐30.0)	.31
Idiopathic IMT		2 (40%)	29 (62%)	.38
Secondary IMT		3 (60%)	18 (38%)
IMHA‐IMT (n = 24)		n = 5	n = 19
Hematocrit	L/L	0.13 (0.11‐0.14)	0.13 (0.11‐0.20)	.48
Reticulocytes	109/L	18 (2‐31)	114 (99‐244)	.002*
Platelets	109/L	71 (35‐83)	40 (21‐85)	.52
Bilirubin	μmol/L	30.9 (18.2‐49.9)	17.1 (7.1‐24.7)	.2
APPLEfast score c		26.0 (25.3‐28.3)	27.0 (25.3‐30.0)	.49
Idiopathic IMHA‐IMT		3 (60%)	14 (74%)	.61
Secondary IMHA‐IMT		2 (40%)	5 (26%)

Note: Numerical data are presented as median (IQR) and proportions as numbers (%).

Abbreviations: APPLE, acute patient physiologic and laboratory evaluation; IMHA, immune‐mediated hemolytic anemia; IMHA‐IMT, immune‐mediated hemolytic anemia and thrombocytopenia; IMT, immune‐mediated thrombocytopenia.

^aIMHA: the APPLE_fast score could be calculated for 5/7 mTPE dogs (71%) and 14/63 control dogs (22%).

^bIMT: the APPLE_fast score could be calculated for 5/5 mTPE dogs (100%) and 11/47 control dogs (23%).

^cIMHA‐IMT: the APPLE_fast score could be calculated for 4/5 mTPE dogs (80%) and 8/19 control dogs (42%).

^*Indicates a statistically significant difference